Scleroderma Experts from Johns Hopkins, Northwestern and Stanford to Explain Symptoms and Treatment Options
A Free Webinar provided by the Scleroderma Research Foundation with support from Gilead Sciences, MedImmune and Novartis
SAN FRANCISCO, May 16, 2013 /PRNewswire-USNewswire/ — The nonprofit Scleroderma Research Foundation (SRF) will welcome Drs. Monique Hinchcliff, Lorinda Chung and Laura Hummers as featured speakers for the popular webinar series helping patients and caregivers to better understand the disease as well as what is being done to find a cure and what new treatments are on the horizon.
May 22, 2013 10:00 AM PDT – Dr. Monique Hinchcliff, Director of Translational Research at the Northwestern Scleroderma Program will share her insights on how to manage scleroderma and its complications.
July 12, 2013 10:30 AM PDT – Dr. Lorinda Chung, Director of the Stanford University Scleroderma Center will discuss skin manifestations in scleroderma.
September 17, 2013 10:00 AM PDT – Dr. Laura Hummers Co-Director of the Johns Hopkins Scleroderma Center of Excellence will share what is new in the world of scleroderma.
“Our goal is not only to educate scleroderma patients, but also to raise awareness and provide a valuable library of resources for those who care for them,” explains SRF Executive Director Amy Hewitt. “Webinars can be viewed live with the opportunity for questions to be answered, or downloaded later on the Foundation’s website.”
Register online at www.sclerodermaRESEARCH.org.
About Scleroderma Research Foundation:
The Scleroderma Research Foundation is America’s leading nonprofit investor in scleroderma research. It was founded in San Francisco in 1987 by scleroderma patient Sharon Monsky who lost her battle to the disease in 2002. Monsky’s legacy lives on through the organization, chaired by Luke Evnin, Ph.D., a scleroderma patient and managing partner of MPM Capital, one of the world’s largest dedicated investors in life sciences.
The Foundation’s collaborative approach is empowering scientists from leading institutions to work together and develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.
SOURCE Scleroderma Research Foundation